BCAX · Bicara Therapeutics Inc. · Insider Trading

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.26 to $23.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.26 to $23.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

25% of the shares subject to this option vest and become exercisable on August 12, 2027, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.56 to $28.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.675 to $28.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.13 to $28.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.23 to $30.205, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.25 to $30.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.21 to $29.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.23 to $30.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.25 to $30.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.22 to $29.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund") and R.A. Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

1. The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Represents the grant of a stock option to Jake Simson pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying this option shall vest upon the earlier of (i) June 9, 2027, and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to Dr. Simson's continued service on such vesting date.

RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.25 to $20.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.52 to $20.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.25 to $20.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.08 to $20.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.08 to $20.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.